American Journal of Clinical and Experimental Medicine

| Peer-Reviewed |

Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors

Received: Oct. 16, 2019    Accepted: Nov. 06, 2019    Published: Nov. 27, 2019
Views:       Downloads:

Share This Article

Abstract

To conduct a study project on the inactivation of pathogens in whole blood using acridine derivatives in Africa, in order to prevent the transmission of pathogens, it is important to look for possible immunization to acridine in the blood donor population. It is therefore important to undertake an estimate of the prevalence in the sub-Saharan population in order to guide the design of the clinical study that will use the INTERCEPT Red Blood System procedure on whole blood for transfusion. to define the starting point in the evaluation of the immunological safety and transfusion safety of the product treated by this process. The objective of this study is to determine the prevalence of AAA among blood donors in sub-Saharan Africa. We conducted a multicenter prospective descriptive study of 902 blood donors collected in Côte d'Ivoire, Benin and Cameroon over the period from June 2015 to January 2017. Blood samples were collected from voluntary blood donors, of any sex, aged between 18 and 65, having given their consent for the study and having participated in the medical consultation for the donation of blood. The samples were analyzed according to the technique of the RAI gel card of the company BIORAD after centrifugation and incubation using test red cells treated with S-303 and glutathione. In the case of positive RAI results, to confirm the presence of anti-acridine, the donor plasma should be incubated with S-300. S-300 is a degradation product of S-303. The donor serum and S-300 are then incubated with the same red test cells. S-300 binds to the antibody and produces a negative result in the gel map in the presence of anti-acridin antibodies. Of the 903 samples tested both at the Abidjan laboratory in Côte D'Ivoire and at the Frankfurt laboratory, we found 1 positive sample and 8 reactive samples (positive for anti-erythrocyte antibodies). Positive donor plasma was incubated with S-300 which is the degradation product of S-303. The result is always positive, whereas according to the instructions of the reference laboratory of Frankfurt, it should be negative in case of presence of Locustacan. The results on AAA testing among 903 donors in three sub-Saharan countries show the absence of AAA in the sample of subjects included in the study according to the hypothesis emitted from this study. This opens the door to the prospect of conducting a clinical study on the inactivation of pathogens by acridine derivatives.

DOI 10.11648/j.ajcem.20190706.11
Published in American Journal of Clinical and Experimental Medicine ( Volume 7, Issue 6, November 2019 )
Page(s) 126-129
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Acridine, Immunization, Subsaharian, Blood Donors

References
[1] Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010; 8: 186-192.
[2] Mirasol Clinical Evaluation Study Group (2010) A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-2375.
[3] Johnson L, Winter KM, Reid S, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101: Acridine–Wikipedia. Disponible sur https://fr.wikipedia.org/wiki/Acridine.
[4] Ramesh Kumar, Mandeep Kaur And Meena Kumari Acridine: A Versatile Heterocyclic Nucleus Acta Poloniae Pharmaceutica Drug Research, 2012; 69 (1): 3-9.
[5] Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood and red blood cells with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38: 14-9.
[6] Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011; 38: 33-42.
[7] So-Yong Kwon, I S Kim, J. E. Bae and Al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sanguinis, 2014; 107 (3).
[8] Winter KM, Johnson L, Kwok M, Vidovic D, Hyland RA, Mufti N, et al. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 2014; 54 (7): 1798-807.
[9] Erickson A, Donnelly B, Schott M, et al. In vitro evaluation of pathogen inactivated RBC using the S-303 treatment system. Transfusion 2012; 52: 77A.
[10] Erickson A, Schott MA, Sherman C, et al. In vitro evaluation of pathogen inactivated RBC using the S-303 treatment system [abstract]. Vox Sang 2011; 101: 78.
[11] North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011; 51: 2208-18.
[12] Organic syntheses. In Synthesis of acridone 19: 6; Coll. Vol. 2: 15 orgsyn. org [archives} from o-chlorobenzoic acid and aniline in a Goldberg reaction.
[13] Organic syntheses. Synthesis of 9-aminoacridine 22: 5; Coll. Vol. 3: 53. orgsyn. org [archive}] from N-phenylanthranilic acid.
[14] Gerard P. Moloney, David P. Kelly, P. Mack Synthesis of Acridine-based DNA Bis-intercalating Agents Molecules 2001; 6: 230-243.
[15] C. Geisen, V. Brixner, L. Stempniewski, A. North, A.-H. Kiessling, M. M. Müller, N. Mufti, E. Seifried. Characterization of preexisting antibodies to S-303 pathogen inactivated red blood cells (S-303 RBC) in patient sera. International Society of Blood Transfusion (ISBT) congress, Septembre 2014, Seoul.
Cite This Article
  • APA Style

    Sekongo Yassongui Mamadou, Dasse Sery Romuald, Altemeyer Anaïs, Soraya Amar, Tayou Claude, et al. (2019). Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors. American Journal of Clinical and Experimental Medicine, 7(6), 126-129. https://doi.org/10.11648/j.ajcem.20190706.11

    Copy | Download

    ACS Style

    Sekongo Yassongui Mamadou; Dasse Sery Romuald; Altemeyer Anaïs; Soraya Amar; Tayou Claude, et al. Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors. Am. J. Clin. Exp. Med. 2019, 7(6), 126-129. doi: 10.11648/j.ajcem.20190706.11

    Copy | Download

    AMA Style

    Sekongo Yassongui Mamadou, Dasse Sery Romuald, Altemeyer Anaïs, Soraya Amar, Tayou Claude, et al. Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors. Am J Clin Exp Med. 2019;7(6):126-129. doi: 10.11648/j.ajcem.20190706.11

    Copy | Download

  • @article{10.11648/j.ajcem.20190706.11,
      author = {Sekongo Yassongui Mamadou and Dasse Sery Romuald and Altemeyer Anaïs and Soraya Amar and Tayou Claude and Anani Ludovic and Kassogue Kadidia and Geisen Cristof and Herbrich Anne and Kouamenan Sidonie and Konate Seidou},
      title = {Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors},
      journal = {American Journal of Clinical and Experimental Medicine},
      volume = {7},
      number = {6},
      pages = {126-129},
      doi = {10.11648/j.ajcem.20190706.11},
      url = {https://doi.org/10.11648/j.ajcem.20190706.11},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ajcem.20190706.11},
      abstract = {To conduct a study project on the inactivation of pathogens in whole blood using acridine derivatives in Africa, in order to prevent the transmission of pathogens, it is important to look for possible immunization to acridine in the blood donor population. It is therefore important to undertake an estimate of the prevalence in the sub-Saharan population in order to guide the design of the clinical study that will use the INTERCEPT Red Blood System procedure on whole blood for transfusion. to define the starting point in the evaluation of the immunological safety and transfusion safety of the product treated by this process. The objective of this study is to determine the prevalence of AAA among blood donors in sub-Saharan Africa. We conducted a multicenter prospective descriptive study of 902 blood donors collected in Côte d'Ivoire, Benin and Cameroon over the period from June 2015 to January 2017. Blood samples were collected from voluntary blood donors, of any sex, aged between 18 and 65, having given their consent for the study and having participated in the medical consultation for the donation of blood. The samples were analyzed according to the technique of the RAI gel card of the company BIORAD after centrifugation and incubation using test red cells treated with S-303 and glutathione. In the case of positive RAI results, to confirm the presence of anti-acridine, the donor plasma should be incubated with S-300. S-300 is a degradation product of S-303. The donor serum and S-300 are then incubated with the same red test cells. S-300 binds to the antibody and produces a negative result in the gel map in the presence of anti-acridin antibodies. Of the 903 samples tested both at the Abidjan laboratory in Côte D'Ivoire and at the Frankfurt laboratory, we found 1 positive sample and 8 reactive samples (positive for anti-erythrocyte antibodies). Positive donor plasma was incubated with S-300 which is the degradation product of S-303. The result is always positive, whereas according to the instructions of the reference laboratory of Frankfurt, it should be negative in case of presence of Locustacan. The results on AAA testing among 903 donors in three sub-Saharan countries show the absence of AAA in the sample of subjects included in the study according to the hypothesis emitted from this study. This opens the door to the prospect of conducting a clinical study on the inactivation of pathogens by acridine derivatives.},
     year = {2019}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors
    AU  - Sekongo Yassongui Mamadou
    AU  - Dasse Sery Romuald
    AU  - Altemeyer Anaïs
    AU  - Soraya Amar
    AU  - Tayou Claude
    AU  - Anani Ludovic
    AU  - Kassogue Kadidia
    AU  - Geisen Cristof
    AU  - Herbrich Anne
    AU  - Kouamenan Sidonie
    AU  - Konate Seidou
    Y1  - 2019/11/27
    PY  - 2019
    N1  - https://doi.org/10.11648/j.ajcem.20190706.11
    DO  - 10.11648/j.ajcem.20190706.11
    T2  - American Journal of Clinical and Experimental Medicine
    JF  - American Journal of Clinical and Experimental Medicine
    JO  - American Journal of Clinical and Experimental Medicine
    SP  - 126
    EP  - 129
    PB  - Science Publishing Group
    SN  - 2330-8133
    UR  - https://doi.org/10.11648/j.ajcem.20190706.11
    AB  - To conduct a study project on the inactivation of pathogens in whole blood using acridine derivatives in Africa, in order to prevent the transmission of pathogens, it is important to look for possible immunization to acridine in the blood donor population. It is therefore important to undertake an estimate of the prevalence in the sub-Saharan population in order to guide the design of the clinical study that will use the INTERCEPT Red Blood System procedure on whole blood for transfusion. to define the starting point in the evaluation of the immunological safety and transfusion safety of the product treated by this process. The objective of this study is to determine the prevalence of AAA among blood donors in sub-Saharan Africa. We conducted a multicenter prospective descriptive study of 902 blood donors collected in Côte d'Ivoire, Benin and Cameroon over the period from June 2015 to January 2017. Blood samples were collected from voluntary blood donors, of any sex, aged between 18 and 65, having given their consent for the study and having participated in the medical consultation for the donation of blood. The samples were analyzed according to the technique of the RAI gel card of the company BIORAD after centrifugation and incubation using test red cells treated with S-303 and glutathione. In the case of positive RAI results, to confirm the presence of anti-acridine, the donor plasma should be incubated with S-300. S-300 is a degradation product of S-303. The donor serum and S-300 are then incubated with the same red test cells. S-300 binds to the antibody and produces a negative result in the gel map in the presence of anti-acridin antibodies. Of the 903 samples tested both at the Abidjan laboratory in Côte D'Ivoire and at the Frankfurt laboratory, we found 1 positive sample and 8 reactive samples (positive for anti-erythrocyte antibodies). Positive donor plasma was incubated with S-300 which is the degradation product of S-303. The result is always positive, whereas according to the instructions of the reference laboratory of Frankfurt, it should be negative in case of presence of Locustacan. The results on AAA testing among 903 donors in three sub-Saharan countries show the absence of AAA in the sample of subjects included in the study according to the hypothesis emitted from this study. This opens the door to the prospect of conducting a clinical study on the inactivation of pathogens by acridine derivatives.
    VL  - 7
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Department of Training and Research, National Blood Transfusion Center, Abidjan; C?te D’Ivoire

  • Hospitality and University Center of Cocody, Abidjan, C?te D’Ivoire

  • Transfusion Swiss Red Cross, Bernn, Switzerland

  • Haematology and Blood Transfusion Service of University Teaching Hospital, Yaoundé, Cameroon

  • Blood Transfusion Agency, Cotonou, Benin

  • Department of Training and Research, National Blood Transfusion Center, Abidjan; C?te D’Ivoire

  • Laboratory, Institute of Transfusion Medicine and Immunohematology, Frankfurt, German

  • Laboratory, Institute of Transfusion Medicine and Immunohematology, Frankfurt, German

  • Department of Training and Research, National Blood Transfusion Center, Abidjan; C?te D’Ivoire

  • The National Blood Transfusion Center, Abidjan, C?te d’Ivoire

  • Section